Company News Archive
PBS listing announced for treatment of unresectable or metastatic, well-differentiated extra-pancreatic or pancreatic neuroendocrine tumours
Ipsen Australia welcomes the Pharmaceutical Benefits Scheme (PBS) listing of Cabometyx® (cabozantinib) for the treatment of patients with unresectable or metastatic, well-differentiated extra-pancreatic neuroendocrine tumour (epNET) or pancreatic neuroendocrine tumour…
QBiotics reports 80% objective response rate in injected tumours in Stage I of Phase IIA soft tissue sarcoma trial
QBiotics Group Limited (QBiotics) announced final efficacy and safety results from the first stage of its two-part Phase IIA clinical trial in patients with Soft Tissue Sarcoma (STS), coinciding with…
